Show simple item record

dc.contributor.authorSavage, SA
dc.contributor.authorBaker, J
dc.contributor.authorMilton, F
dc.contributor.authorButler, C
dc.contributor.authorZeman, A
dc.date.accessioned2022-03-29T09:15:31Z
dc.date.issued2022-03-06
dc.date.updated2022-03-28T15:11:56Z
dc.description.abstractOBJECTIVE: Transient epileptic amnesia (TEA) is a form of adult-onset epilepsy where presenting features are well described, but little is known regarding prognosis. This study aimed to elucidate the long-term prognosis of TEA regarding seizure control, memory, medical comorbidities, and life expectancy. METHODS: Up-to-date clinical information was collected for 47 people diagnosed with TEA who had joined the The Impairment of Memory in Epilepsy (TIME) study 10 years earlier. At entry to the study, information about comorbid conditions was systematically collected. Details regarding subsequent diagnoses, seizure activity, changes to treatment, or reports of cognitive impairment were obtained through the family doctor. The variables of interest were compared with UK population data. RESULTS: Mortality in the cohort was 21 of 47 (45%), with an average age at death of 82.5 years. Seizures remained well controlled for the majority but medications required adjustments in dose and type for some (28%). A small number (three cases) remained seizure-free without medication. History of cardiovascular disorders was frequent (78.7%), typically involving hypertension (55.3%). Autoimmune disorders (25.5%), cancer (23.4%), and depression (21.3%) were also commonly reported. Although persisting memory problems were often noted, dementia was diagnosed in seven cases (14.9%). Life expectancy and comorbidities in TEA did not differ from available population norms. SIGNIFICANCE: Results suggest that life expectancy is not reduced in TEA. Although TEA does not appear to be a self-limiting form of epilepsy, seizures are typically well controlled via medication. Because adjustments to medication may be required, even after long periods of stability, ongoing medical monitoring is recommended. Comorbid vascular disorders are frequent but appear similar to general population estimates. Monitoring mood may be important, given that people with chronic conditions are often vulnerable to depression. Because of persisting memory difficulties, the development of effective memory interventions for people with TEA is warranted.en_GB
dc.description.sponsorshipDunhill Medical Trusten_GB
dc.description.sponsorshipMedical Research Council (MRC)en_GB
dc.description.sponsorshipAlzheimer's Societyen_GB
dc.format.mediumPrint-Electronic
dc.identifier.citationPublished online 6 March 2022en_GB
dc.identifier.doihttps://doi.org/10.1111/epi.17214
dc.identifier.grantnumberR322/1113en_GB
dc.identifier.grantnumberMR/K010395/1en_GB
dc.identifier.grantnumber231en_GB
dc.identifier.urihttp://hdl.handle.net/10871/129191
dc.identifierORCID: 0000-0003-2586-7658 (Milton, Fraser)
dc.language.isoenen_GB
dc.publisherWiley / International League Against Epilepsyen_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/35253220en_GB
dc.rights© 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.en_GB
dc.subjectadult-onset epilepsyen_GB
dc.subjectclinical outcomeen_GB
dc.subjectcognitive impairmenten_GB
dc.subjectcomorbiditiesen_GB
dc.subjectmemoryen_GB
dc.titleClinical outcomes in transient epileptic amnesia: A 10-year follow-up cohort study of 47 casesen_GB
dc.typeArticleen_GB
dc.date.available2022-03-29T09:15:31Z
dc.identifier.issn0013-9580
exeter.place-of-publicationUnited States
dc.descriptionThis is the final version. Available on open access from Wiley via the DOI in this recorden_GB
dc.identifier.eissn1528-1167
dc.identifier.journalEpilepsiaen_GB
dc.relation.ispartofEpilepsia
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_GB
dcterms.dateAccepted2022-03-03
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2022-03-06
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2022-03-28T15:12:00Z
refterms.versionFCDAM
refterms.dateFOA2022-03-29T09:15:44Z
refterms.panelAen_GB
refterms.dateFirstOnline2022-03-18


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
Except where otherwise noted, this item's licence is described as © 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.